Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

被引：0
作者：
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Dena DeMarco
Jingshan Zhang
Jay Mei
Jian Hou
机构：
[1] Guangdong General Hospital,The 1st Affiliated Hospital
[2] Zhejiang University,Department of Hematology
[3] Xiangya Hospital of Central South University,undefined
[4] Peking Union Medical College Hospital,undefined
[5] The 301 Hospital-Chinese PLA General Hospital,undefined
[6] Peking University Third Hospital,undefined
[7] Shanghai 6th Hospital,undefined
[8] The 1st Affiliated Hospital of Soochow University,undefined
[9] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[10] Celgene Corporation,undefined
[11] Shanghai Changzheng Hospital,undefined
来源：
BMC Cancer | / 16卷
关键词：
Relapsed/refractory multiple myeloma; Chinese patients; Lenalidomide; Low-dose dexamethasone; Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Parisi, Marina Silvia
    Leotta, Salvatore
    Romano, Alessandra
    Del Fabro, Vittorio
    Martino, Enrica Antonia
    Calafiore, Valeria
    Giubbolini, Rachele
    Markovic, Uros
    Leotta, Valerio
    Di Giorgio, Mary Ann
    Tibullo, Daniele
    Di Raimondo, Francesco
    Conticello, Concetta
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [22] DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Khouri, Jack
    Faiman, Beth M.
    Grabowski, Dale
    Mahfouz, Reda Z.
    Khan, Shahper N.
    Wei, Wei
    Valent, Jason
    Dean, Robert
    Samaras, Christy
    Jha, Babal K.
    Lazarus, Hillard
    Campagnaro, Erica L.
    Malek, Ehsan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Sobecks, Ronald
    Saunthararajah, Yogen
    Chew, Yap
    Orloff, Mohammed
    Reu, Frederic J.
    SEMINARS IN HEMATOLOGY, 2021, 58 (01) : 45 - 55
  • [23] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
    Fu, Wei-Jun
    Wang, Ya-Fei
    Zhao, Hong-Guo
    Niu, Ting
    Fang, Bai-Jun
    Liao, Ai-Jun
    Bai, Hai
    Lu, Jin
    BMC CANCER, 2022, 22 (01)
  • [24] Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Chen, C.
    Spencer, A.
    Niesvizky, R.
    Attal, M.
    Stadtmauer, E. A.
    Petrucci, M. T.
    Yu, Z.
    Olesnyckyj, M.
    Zeldis, J. B.
    Knight, R. D.
    Weber, D. M.
    LEUKEMIA, 2009, 23 (11) : 2147 - 2152
  • [25] Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    C Chen
    A Spencer
    R Niesvizky
    M Attal
    E A Stadtmauer
    M T Petrucci
    Z Yu
    M Olesnyckyj
    J B Zeldis
    R D Knight
    D M Weber
    Leukemia, 2009, 23 : 2147 - 2152
  • [26] Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma
    Murakami, Hirokazu
    Handa, Hiroshi
    Abe, Masahiro
    Iida, Sinsuke
    Ishii, Akihiro
    Ishikawa, Takayuki
    Ishida, Tadao
    Oota, Masatsugu
    Ozaki, Shuji
    Kosaka, Masaaki
    Sakai, Akira
    Sawamura, Morio
    Shimazaki, Chihiro
    Shimizu, Kazuyuki
    Takagi, Toshiyuki
    Hata, Hiroyuki
    Fukuhara, Takashi
    Fujii, Hiroshi
    Miyata, Akira
    Wakayama, Toshio
    Takatsuki, Kiyoshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (03) : 234 - 239
  • [27] Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
    Zago, Manola
    Oehrlein, Katharina
    Rendl, Corinna
    Hahn-Ast, Corinna
    Kanz, Lothar
    Weisel, Katja
    ANNALS OF HEMATOLOGY, 2014, 93 (12) : 1993 - 1999
  • [28] Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome
    Cai, Qian-Qian
    Wang, Chen
    Cao, Xin-Xin
    Cai, Hao
    Zhou, Dao-Bin
    Li, Jian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 325 - 330
  • [29] Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma
    Popat, Rakesh
    Oakervee, Heather
    Williams, Catherine
    Cook, Mark
    Craddock, Charles
    Basu, Supratik
    Singer, Charles
    Harding, Stephen
    Foot, Nicola
    Hallam, Simon
    Odeh, Liz
    Joel, Simon
    Cavenagh, Jamie
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (06) : 887 - 894
  • [30] Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
    Manola Zago
    Katharina Oehrlein
    Corinna Rendl
    Corinna Hahn-Ast
    Lothar Kanz
    Katja Weisel
    Annals of Hematology, 2014, 93 : 1993 - 1999
12345